Caner Saygin to Survival Rate
This is a "connection" page, showing publications Caner Saygin has written about Survival Rate.
Connection Strength
0.248
-
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 12; 95(12):1457-1465.
Score: 0.136
-
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018 01 10; 8(1):4.
Score: 0.113